CD19-CD22 CAR-T / Shanghai Ultra-T Immune Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  KQ-2003 / Shanghai Keqi Pharma
    Trial completion date, Trial primary completion date, CAR T-Cell Therapy:  Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) -  Dec 28, 2023   
    P1/2,  N=24, Recruiting, 
    Trial completion date: Dec 2023 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2024 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jan 2022 --> Sep 2024